Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo.
about
Accelerated aging in glaucoma: immunohistochemical assessment of advanced glycation end products in the human retina and optic nerve headSerum Levels of Toxic AGEs (TAGE) May Be a Promising Novel Biomarker for the Onset/Progression of Lifestyle-Related DiseasesContribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinomaAssessment of the concentrations of various advanced glycation end-products in beverages and foods that are commonly consumed in JapanEffect of Collagen Tripeptide on Atherosclerosis in Healthy HumansToxic AGE (TAGE) Theory for the Pathophysiology of the Onset/Progression of NAFLD and ALDSoluble receptor for advanced glycation end products in critically ill patients and its associations with other clinical markers and 28-day mortality.Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategiesAcetaldehyde-derived advanced glycation end-products promote alcoholic liver diseaseOral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure.In vitro identification of nonalcoholic fatty liver disease-related protein hnRNPM.Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy.Decrease in the glyceraldehyde derived advanced glycation end products in the sera of patients with Vogt-Koyanagi-Harada diseaseOxidative stress in glaucomatous neurodegeneration: mechanisms and consequences.Glyceraldehyde caused Alzheimer's disease-like alterations in diagnostic marker levels in SH-SY5Y human neuroblastoma cellsPositive association between serum level of glyceraldehyde-derived advanced glycation end products and vascular inflammation evaluated by [(18)F]fluorodeoxyglucose positron emission tomography.Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: the JAPAN-ACS sub-study.DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy.Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report.Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury.Generation of glyceraldehyde-derived advanced glycation end-products in pancreatic cancer cells and the potential of tumor promotionAdvanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression.Neuropathy induced by exogenously administered advanced glycation end-products in rats.MK615 decreases RAGE expression and inhibits TAGE-induced proliferation in hepatocellular carcinoma cells.Glyceraldehyde-Derived Advanced Glycation End Products Accumulate Faster Than Nε-(Carboxymethyl) Lysine.Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy.Ciprofloxacin inhibits advanced glycation end products-induced adhesion molecule expression on human monocytes.Glycer-AGEs-RAGE signaling enhances the angiogenic potential of hepatocellular carcinoma by upregulating VEGF expression.Cancer malignancy is enhanced by glyceraldehyde-derived advanced glycation end-productsTriosidines: novel Maillard reaction products and cross-links from the reaction of triose sugars with lysine and arginine residues.Glyceraldehyde-derived pyridinium (GLAP) evokes oxidative stress and inflammatory and thrombogenic reactions in endothelial cells via the interaction with RAGE.Impact of intracellular glyceraldehyde-derived advanced glycation end-products on human hepatocyte cell death.Activation of NLRP3 Inflammasome by Advanced Glycation End Products Promotes Pancreatic Islet Damage.Effects of scavenger receptors-1 class A stimulation on macrophage morphology and highly modified advanced glycation end product-protein phagocytosis.
P2860
Q22306304-E4300F9F-0379-4A6B-99E5-D25D8D7D44AAQ26747425-6C9D42CF-FC45-46E7-85E2-68B36D02E503Q26781477-8A825867-6263-4384-82D8-890FA40CE808Q28543766-F78A6565-5393-4BAE-9EBD-2440AB7F12CDQ33676014-94CC878C-6280-4830-BFC5-393479DE4CA2Q33852213-96168E2B-95A4-4102-8C36-157A2726582CQ34564061-587879E2-1D62-46AA-B12B-B8C4781488BCQ34728267-63D41DC0-B990-400F-A7B0-955AA7A148F4Q34905489-037F74C5-1157-430D-8816-B4F319600FFEQ35113743-0EB744F4-188E-4917-B11F-D41EEE23161FQ35561941-C6B81638-4BCA-48FF-9A88-41653962F50FQ35593254-62EE71CD-B9AA-4FD6-A2A6-9784445C0128Q35593900-4DF71A44-C4A5-4923-8929-A2BBBD740D8FQ35677091-DD1D660B-AC0E-41F0-8412-4B1AAE12F9F0Q35993403-3CBEB990-F8C2-4ABC-9469-99ED53271D9AQ36426832-C627084A-D075-43B1-AAA3-36CCE8B7E61AQ36608513-7013BC8B-B134-4960-802D-7CE175586100Q37110641-B7984D4D-2AB3-4DD8-B770-9DCA7A3C7DCBQ37541529-A49A9031-6D76-4055-9C9E-E3353C5C4CB7Q38359414-EE72BD22-225D-4F0F-BFE8-237FB16925C7Q38695562-F62D8760-32B4-419A-AAE5-28BD5DFEE6BAQ38895998-4AFF6C46-9D51-41CC-9309-C1414092EE85Q39603238-87B95BCA-0057-4A34-977E-918E71A5B982Q39632617-34231626-2A8D-4B64-9F66-A047E6CB2B90Q40955558-BB6D1DC9-614F-4012-9C03-E87E43CD0FDDQ41789363-BF69E468-FEFF-4787-90A8-DE79FF11A571Q42067799-80CB06C6-4A8F-4807-AF82-05156A1131C1Q42204462-4B7FC598-E31F-46C1-916D-710E28314D58Q42734294-8DE44D5D-54DF-4298-A107-4D60485FEB2EQ43002603-6CCE948C-53C4-48A0-ABAA-48B7DB8909B5Q43111677-D1B1B0E8-8466-4D19-9296-22C5479FA89FQ43951595-2461630D-1BE0-4163-A681-A72C70CB3EEBQ47166089-9F555608-9FA2-44D0-8829-3E85BE05A0F1Q52590915-901B9BF4-859F-4827-9417-6E0393EAE25A
P2860
Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Immunological evidence that no ...... dicarbonyl compounds in vivo.
@en
Immunological evidence that no ...... dicarbonyl compounds in vivo.
@nl
type
label
Immunological evidence that no ...... dicarbonyl compounds in vivo.
@en
Immunological evidence that no ...... dicarbonyl compounds in vivo.
@nl
prefLabel
Immunological evidence that no ...... dicarbonyl compounds in vivo.
@en
Immunological evidence that no ...... dicarbonyl compounds in vivo.
@nl
P2093
P1433
P1476
Immunological evidence that no ...... dicarbonyl compounds in vivo.
@en
P2093
P304
P407
P50
P577
2000-02-01T00:00:00Z